Literature DB >> 16495752

Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension.

Chang-Ming Chern1, Hung-Yi Hsu, Han-Hwa Hu, Yen-Yu Chen, Li-Chi Hsu, A-Ching Chao.   

Abstract

Baroreflex sensitivity (BRS) and heart rate variability (HRV) are potential therapeutic targets. The present study was conducted to assess changes in BRS and HRV after monotherapy with losartan versus that of atenolol in uncomplicated essential hypertension. Thirty subjects with uncomplicated essential hypertension were randomized to receive atenolol 50 mg to 100 mg (n = 15) or losartan 50 mg to 100 mg (N = 15) daily for 6 months. Instantaneous systolic blood pressure (SBP) and heart rate were assessed using servo-controlled infrared finger plethysmography before treatment and at the end of 3 months and 6 months after treatment. The fluctuation in SBP and interpulse interval (IPI) was divided into three specific frequency ranges by fast Fourier transform as high frequency (HF; 0.15 Hz-0.4 Hz), low frequency (LF; 0.04 Hz-0.15 Hz), and very low frequency (VLF; 0.004 Hz-0.04 Hz). The BRS was expressed as (1) SBP-IPI transfer function with its magnitude in the HF and LF ranges and (2) BRS index alpha. The HRV was expressed as total power and power in the LF and HF ranges of interpulse interval. Blood pressure was reduced to a similar extent in both groups. Compared with the baseline, BRS did not improve in both groups at month 3. However, BRS was significantly improved in the losartan group (P < 0.05) but not in the atenolol group at month 6. In addition, BRS was significantly higher in the losartan group than the atenolol group at month 3 and month 6 (P < 0.05). Moreover, heart rate variability was significantly reduced in the atenolol group at month 6 (P < 0.05), but not in the losartan group. The HRV in the losartan group was significantly higher than that in the atenolol group at month 6 (P < 0.05). These findings suggest superior effects of losartan on BRS and HRV than atenolol in uncomplicated essential hypertension, which may be beyond blood pressure reduction/resetting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495752     DOI: 10.1097/01.fjc.0000199225.17928.f5

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Effects of aerobic exercise training and irbesartan on blood pressure and heart rate variability in patients with chronic obstructive pulmonary disease.

Authors:  Karine Marquis; Fracois Maltais; Yves Lacasse; Yves Lacourciere; Claudette Fortin; Paul Poirier
Journal:  Can Respir J       Date:  2008-10       Impact factor: 2.409

2.  Baroreflex gain and vasomotor sympathetic modulation in resistant hypertension.

Authors:  Isabelle Magalhães Guedes Freitas; Leonardo Barbosa de Almeida; Natália Portela Pereira; Pedro Augusto de Carvalho Mira; Rogério Baumgratz de Paula; Daniel Godoy Martinez; Edgar Toschi-Dias; Mateus Camaroti Laterza
Journal:  Clin Auton Res       Date:  2017-04-06       Impact factor: 4.435

Review 3.  Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.

Authors:  David Feldman; Terry S Elton; Doron M Menachemi; Randy K Wexler
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

4.  Sympathetic activation and baroreflex function during intradialytic hypertensive episodes.

Authors:  Dvora Rubinger; Rebecca Backenroth; Dan Sapoznikov
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

Review 5.  Autonomic dysfunction in essential hypertension: A systematic review.

Authors:  Elliott R Carthy
Journal:  Ann Med Surg (Lond)       Date:  2013-12-11

Review 6.  The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy.

Authors:  Danai-Thomais Kostourou; Dimitrios Milonas; Georgios Polychronopoulos; Areti Sofogianni; Konstantinos Tziomalos
Journal:  J Pers Med       Date:  2022-07-30

7.  A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension.

Authors:  Wei-Jun Zhou; Ren-Ying Wang; Yan Li; Dong-Rui Chen; Er-Zhen Chen; Ding-Liang Zhu; Ping-Jin Gao
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

8.  Sympathoactivation and rho-kinase-dependent baroreflex function in experimental renovascular hypertension with reduced kidney mass.

Authors:  Rainer U Pliquett; Sebastian Benkhoff; Oliver Jung; Ralf P Brandes
Journal:  BMC Physiol       Date:  2014-06-19

9.  Visit-to-visit HbA1c variability is inversely related to baroreflex sensitivity independently of HbA1c value in type 2 diabetes.

Authors:  Daisuke Matsutani; Masaya Sakamoto; Soichiro Minato; Yosuke Kayama; Norihiko Takeda; Ryuzo Horiuchi; Kazunori Utsunomiya
Journal:  Cardiovasc Diabetol       Date:  2018-07-10       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.